About Lantheus Holdings Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lantheus.com/
Frequently Asked Questions
What is the 52-week range for LNTH?
The 52-week high is $111.86 and the 52-week low is $49.67.
What is the P/E ratio for LNTH?
The Price to Earnings (P/E) ratio is 23.71.
What is the dividend yield for LNTH?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 23.27%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 17.69%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.05.
Analyst Recommendation Trends
Wall Street analyst consensus for LNTH over the last few months:
Latest LNTH News
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Centers for Medicare & Medicaid
Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluati
Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401
Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval
FDA approval for BRAVNETSA puts Lantheus Holdings (LNTH) in focus Lantheus Holdings (LNTH) drew fresh attention after the FDA granted final approval for BRAVNETSA, a radiopharmaceutical considered bioequivalent and therapeutically equivalent to LUTATHERA for adult GEP NET patients. The BRAVNETSA approval lands at a time when Lantheus Holdings has seen short term share price pressure, with the stock down over the past three months. Yet its year to date share price return of 48.27% and 1 year...
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval
Lantheus Holdings has delivered a powerful 5 year share price run, and the recent pullback leaves investors asking whether the current US$99.74 level is still grounded in the cash the business can generate. With fresh product news in its core radiopharmaceutical line, the question now is how far those future cash flows can stretch to back up today's valuation. Over the past 5 years the stock has returned 285.5%, which puts real pressure on the cash flow outlook to carry that kind of value...
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally
Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]
3 Reasons LNTH is Risky and 1 Stock to Buy Instead
Lantheus currently trades at $100.02 and has been a dream stock for shareholders. It’s returned 270% since September 2021, blowing past the S&P 500’s 74.5% gain. The company has also beaten the index over the past six months as its stock price is up 32.1% thanks to its solid quarterly results.
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs)BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Admini
2 Small-Cap Stocks to Consider Right Now and 1 That Underwhelm
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Marshall Robert J. Jr. | -721 | $100.96 | $72,792 |
| 2026-08-17 | Dinkelborg Ludger | -2,536 | $100.91 | $255,908 |
| 2026-08-17 | Brown Kimberly | -463 | $100.91 | $46,721 |
| 2026-05-14 | Ber Gerard | -381 | $96.67 | $36,831 |
| 2026-05-14 | Heino Mary Anne | -1,227 | $96.67 | $118,614 |
| 2026-05-14 | Morrow Phuong Khanh | +4,137 | - | - |
| 2026-05-14 | Maeusli Heinz Christoph | +4,137 | - | - |
| 2026-05-14 | Pruden Gary J | +4,137 | - | - |
| 2026-05-14 | Baylor-Henry Minnie | +4,137 | - | - |
| 2026-05-14 | Ber Gerard | +4,137 | - | - |
| 2026-05-14 | EASTLAND JULIA MARIE | +4,137 | - | - |
| 2026-05-14 | McHugh Julie | +4,137 | - | - |
| 2026-05-14 | Thrall James H | +4,137 | - | - |
| 2026-05-14 | LENO SAM R | +4,137 | - | - |
| 2026-04-17 | Niedzwiecki Daniel | -1,911 | $83.82 | $160,180 |
| 2026-03-05 | Niedzwiecki Daniel | -1,283 | $76.31 | $97,906 |
| 2026-03-05 | Niedzwiecki Daniel | +36,692 | - | - |
| 2026-03-05 | Dinkelborg Ludger | +20,966 | - | - |
| 2026-03-05 | Marshall Robert J. Jr. | -1,182 | $76.31 | $90,198 |
| 2026-03-05 | Marshall Robert J. Jr. | +38,002 | - | - |
| 2026-03-05 | Brown Kimberly | -133 | $76.31 | $10,149 |
| 2026-03-05 | Brown Kimberly | +6,158 | - | - |
| 2026-03-05 | Morgan Amanda Michelle | -595 | $76.31 | $45,404 |
| 2026-03-05 | Morgan Amanda Michelle | +26,208 | - | - |
| 2026-03-02 | Niedzwiecki Daniel | -8,259 | $76.3 | $630,162 |
| 2026-03-02 | Niedzwiecki Daniel | +5,169 | - | - |
| 2026-03-02 | Morgan Amanda Michelle | -3,336 | $76.3 | $254,537 |
| 2026-03-02 | Morgan Amanda Michelle | +2,782 | - | - |
| 2026-03-02 | Marshall Robert J. Jr. | -10,652 | $76.3 | $812,748 |
| 2026-03-02 | Marshall Robert J. Jr. | +8,491 | - | - |
| 2026-03-02 | Heino Mary Anne | -41,916 | $76.3 | $3,198,191 |
| 2026-03-02 | Heino Mary Anne | +32,105 | - | - |
| 2025-12-15 | Morgan Amanda Michelle | -368 | $66.57 | $24,498 |
| 2025-11-17 | Heino Mary Anne | +26,325 | - | - |
| 2025-11-17 | Heino Mary Anne | +14,285 | - | - |